Co-Producer
|
|
| AUGUST
4, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Todd
Dickinson, President & CEO,
Stellaromics |
In
this Q&A, Dickinson explains why
conventional spatial platforms lose
critical biological information by cutting
tissue too thin, how its Pyxa® platform
preserves native tissue architecture in
sections up to 100 microns thick, and what
that means for drug discovery, tumor
biology, and patient care. More
|
|
|
|
|
Join
us September 30 – October 1 for
LSPA’s largest partnering event of
the year. Connect with the life
sciences ecosystem throughout the
Commonwealth and beyond, get the
latest information through timely
panel discussions and learn about
the newest innovations shaping the
industry.
|
|
Learn More
→ |
|
|
- Dr. Reddy: The First-to-Market Launch of
Sugammadex Injection 200 mg/2 mL (100 mg/mL)
and 500 mg/5 mL (100 mg/mL) Single-Dose Vials,
a Generic Equivalent of Bridion, in the United
States More
- Harmony Biosciences: Record Q2 2026 Revenue
and Shares Initial Clinical Data for Its
Orexin-2 Agonist BP-205 Reinforcing Potential
Best-in-Class Profile More
- Otsuka: Unveils Unprecedented Phase 3
VISIONARY Two-Year eGFR Results
Demonstrating VOYXACT (sibeprenlimab-szsi)
Stabilizes Kidney Function Decline to
Baseline Physiologic Rate, Fundamentally
Altering Disease Progression in IgA
Nephropathy (IgAN) More
More
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Certara: Second Quarter 2026 Financial
Results More
- CHOP-Linked Drug Candidate Acquired by
Iceland Biotech More*
- Exicure: Will Settle GPCR Therapeutics
Clinical Milestone Payment Through Equity
Issuance More
- 'It's Making a Difference': Madrigal CEO
Talks Strategy Behind MASH Shopping Spree More
- Larimar Therapeutics: Second Quarter 2026
Financial and Business Update More
- More on An AstraZeneca-Bristol Myers
Megamerger? Wall Street Isn't Thrilled. More
More
More*
More*
- Neuronetics Reaches Accord With Activist
Investor After Sale Pressure More*
- Palvella Therapeutics: Second Quarter 2026
Financial Results and Provides Corporate
Update More
- Teleflex: Completes Strategic Divestiture
of OEM Business for $1.5 Billion More
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Todd
Dickinson, President & CEO, Stellaromics
More
- Boocentury: Ep. 380 - AZ-BMS Rumors,
Replimune, Psychedelics Podcast
- Biotech Hangout: Episode 191 Podcast
- Slone Partners: Premier Executive
Search and Talent Advisory Firm More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- ICYMI: Medicus Pharma Appoints Dr. Faisal
Mehmud as Chief Executive Officer of Antev
Limited, United Kingdom More
- OPPORTUNITY: Chief Scientific Officer,
Manassas, VA
More
- OPPORTUNITY: President, PA More
- OPPORTUNITY: Vice President, Global BD,
Remote More
- Slone Partners: Places Amer Mirza, PhD, as
Chief Scientific Officer at Prolynx More
- Slone Partners: The Convergence of
MedTech and Digital Health - How New Hybrid
Devices Are Reshaping Care Delivery and
Leadership Profiles More
- TELA Bio: Appointment of Heather Getz as
Chief Executive Officer and Director More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Philadelphia Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Philadelphia,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
